APP and early-onset autosomal dominant Alzheimer disease: When usedto immunize mice and non-human primates, optimized ACI-24 demonstrates a strongantibody response to Abeta1–42 as expected, as well as pGlu-Abeta3–42,forms of Abeta that have been demonstrated to be highly amyloidogenic andneurotoxic, driving Alzheimer’s disease progression.